US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted A61KA61K31/352A61P
Quick answer
US patent 12350253 (Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease) held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
- Grant date
- Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/352, A61P, A61P25/16